Imphi 500 Tablet contains Mycophenolate mofetil 500 mg, an immunosuppressive agent primarily used to prevent organ rejection in patients undergoing kidney, heart, or liver transplantation. Mycophenolate mofetil works by inhibiting inosine monophosphate dehydrogenase, a key enzyme involved in the de novo synthesis of guanine nucleotides, thereby suppressing the proliferation of T and B lymphocytes which are critical in the immune response. This selective inhibition reduces the likelihood of graft rejection by modulating the immune system without broadly compromising other cellular functions. Imphi 500 is typically administered as part of a combination therapy with other immunosuppressants such as cyclosporine and corticosteroids to enhance efficacy and minimize rejection risk. The dosage and duration of treatment are individualized based on the type of transplant, patient response, and tolerance. Common adverse effects may include gastrointestinal disturbances, leukopenia, anemia, and increased susceptibility to infections. Regular monitoring of blood counts and renal function is recommended during therapy. Caution is advised in pregnant or breastfeeding women due to potential teratogenic effects. Imphi 500 Tablet should be used under strict medical supervision to ensure optimal therapeutic outcomes and to manage potential adverse reactions effectively.